{"id":44313,"date":"2022-05-25T09:01:53","date_gmt":"2022-05-25T07:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/"},"modified":"2022-05-25T09:01:53","modified_gmt":"2022-05-25T07:01:53","slug":"first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/","title":{"rendered":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology"},"content":{"rendered":"
\n

\nBarcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer<\/i>\n<\/p>\n

<\/a><\/p>\n

PALO ALTO, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d\u2019Hebron Institute of Oncology (VHIO), one of Europe\u2019s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health\u2019s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona.\n<\/p>\n

\nGuardant Health and VHIO established the partnership in January 2021 to give more patients access to Guardant Health\u2019s industry leading liquid biopsy technology. This testing service will provide essential genomic information through comprehensive genomic profiling (CGP) for patients with any solid cancerous tumor. From a simple blood draw, the test identifies patients with actionable biomarkers more quickly than starting with tissue biopsy. The VHIO testing services will be available for clinical research and clinical care.\n<\/p>\n

\n\u201cThe opening of this service will give more patients with advanced cancer access to blood-based biomarker testing and help their healthcare professionals make more informed treatment decisions,\u201d said Helmy Eltoukhy, Guardant Health co-CEO. \u201cWe look forward to continuing to build our partnership with VHIO, working together to ensure cancer patients across Spain and beyond have access to the latest innovations in precision oncology and striving to achieve better patient outcomes.\u201d\n<\/p>\n

\n\u201cThe incorporation of this technology in VHIO will enable us to continue advancing towards precision medicine, improving the use of liquid biopsy to detect genomic alterations in tumors and come out with more effective treatments for patients,\u201d said Dr Josep Tabernero, Director of VHIO and Head of the Medical Oncology Department of Vall d\u2019Hebron University Hospital. \u201cOur goal is to ensure that the use of liquid biopsy becomes a common diagnostic option, so that oncologists can use it to determine the best treatment for their patients. Thanks to this agreement, we can move towards this scenario.\u201d\n<\/p>\n

\n\u201cImplementing this technology in our lab is a leap forward in the liquid field for us. We have performed an in-house extensive analytical validation of the assay and we attain very high levels of sensitivity and specificity with the test,\u201d said Dr Ana Vivancos, Group Leader of the VHIO Cancer Genomics Group, where this testing will take place. \u201cGuardant Health\u2019s next generation broad panel sequencing technology gives us the capabilities to screen for a large number of gene mutations and provides complete genomic results without the need for a tissue sample.\u201d\n<\/p>\n

\nIn 2020, there were over 282,000 new cancer cases in Spain and approximately 113,000 cancer deaths, with lung cancer and colon cancer being the leading causes of cancer-related death.1 <\/sup>Guardant Health\u2019s tests are used by oncologists around the world to guide treatment decisions across solid tumor cancers, and by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development.\n<\/p>\n

\nAbout Guardant Health<\/b>\n<\/p>\n

\nGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360\u00ae, Guardant360 CDx, Guardant360 TissueNext\u2122, Guardant360 Response\u2122, and GuardantOMNI\u00ae tests for advanced stage cancer patients, and Guardant Reveal\u2122 for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield\u2122 test, aims to address the needs of individuals eligible for cancer screening.\n<\/p>\n

\nAbout Vall d\u2019Hebron Institute of Oncology<\/b>\n<\/p>\n

\nEstablished in 2006, the Vall d\u2019Hebron Institute of Oncology (VHIO)<\/a> is a leading comprehensive cancer research center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain\u2019s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology \u2013 turning cancer discovery into more effective treatments and better practice for the care of our patients. VHIO is one of the seven leading European cancer research centers that have joined forces to create Cancer Core Europe, a Cancer Association carrying out innovative research propelling cancer medicine into a new era through translational research.\n<\/p>\n

\nGuardant Health Forward-Looking Statement<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.\n<\/p>\n

\nReferences<\/b>\n<\/p>\n

    \n
  1. \nInternational Agency for Research on Cancer. World Health Organization. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/724-spain-fact-sheets.pdf<\/a>. Accessed online May 18, 2022.\n<\/li>\n<\/ol>\n

    \n\u00a0\n<\/p>\n

    Contacts<\/b> <\/p>\n

    \nGuardant Health Contacts<\/b>\n<\/p>\n

    \nInvestor Contact:<\/b>
    Alex Kleban
    \n
    investors@guardanthealth.com<\/a>
    +1 657-254-5417\n<\/p>\n

    \nMedia Contact:<\/b>
    Michele Rest
    \n
    press@guardanthealth.com<\/a>
    +1 215-910-2138\n<\/p>\n

    \nVall d\u2019Hebron Institute of Oncology Contact<\/b>\n<\/p>\n

    \nMedia Contact:<\/b>
    Bianca Pont
    \n
    bpont@vhio.net<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d\u2019Hebron Institute of Oncology (VHIO), one of Europe\u2019s leading cancer research organizations, today announced … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44313","6":"format-standard","7":"category-industry"},"yoast_head":"\nFirst Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d\u2019Hebron Institute of Oncology (VHIO), one of Europe\u2019s leading cancer research organizations, today announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T07:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology\",\"datePublished\":\"2022-05-25T07:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/\"},\"wordCount\":1049,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005312\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/\",\"name\":\"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005312\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"datePublished\":\"2022-05-25T07:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005312\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005312\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/","og_locale":"en_US","og_type":"article","og_title":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend","og_description":"Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. & BARCELONA, Spain–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d\u2019Hebron Institute of Oncology (VHIO), one of Europe\u2019s leading cancer research organizations, today announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T07:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology","datePublished":"2022-05-25T07:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/"},"wordCount":1049,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/","url":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/","name":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","datePublished":"2022-05-25T07:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220525005312\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/first-guardant-health-liquid-biopsy-testing-service-in-europe-now-operational-at-vall-dhebron-institute-of-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d\u2019Hebron Institute of Oncology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44313"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44313\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}